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Background: Psoriatic arthritis (PsA) disease activities at baseline may determine physical function over time. There
is no longitudinal data on course of physical function in PsA patients from Asia. We aim to describe variables
associated with a deterioration of physical function in PsA in Chinese over a 6-year period.
Methods: 125 consecutive patients with PsA fulfilled the CASPAR criteria from a rheumatology outpatient center
were recruited to give sociodemographic and clinical data in 2006 to 2008. Follow up interviews were conducted
in 2012 to 2013 to assess physical function using Health Assessment Questionnaire (HAQ). Regression models were
constructed to determine baseline variables that predict physical function on follow up.
Results: A total of 97 patients completed the follow up survey, with mean follow up time of 6.2 (±0.7) years,
response rate 77.6%. PsA patients had poor physical function and health related quality of life (HRQoL) compared to
normal population. There were 33% who improved in disability status and 41.2% had persistent minimal disability
by HAQ categories (HAQ 0–0.49) over time. There were 14.4% of the patients who had persistent moderate
disability (HAQ 0.5-1.50) and 10.3% had deterioration in disability status. There were 17.5% of patients who had
deterioration in physical function as defined by an increment of HAQ score of more than 0.2 at follow up survey.
Age, physical function at baseline and the number of damaged joint were significantly related HAQ at follow up.
Conclusion: Chinese patients with PsA had had poor physical function and quality of life. One fifth of patient
experienced deterioration of physical function over time. Joint damage and baseline physical function were
important factors associated with poor physical function in PsA over time.
Keywords: Psoriatic arthritis, Physical function, Longitudinal studyBackground
Psoriatic arthritis (PsA) is an inflammatory arthritis as-
sociated with psoriasis. It affects young adults in their
working ages. It has deleterious effects on patients and
joint deformities and disease progression have been
shown to develop over time [1-4]. We and other investi-
gators have shown that the physical function among
patients with psoriatic arthritis is lower than the normal* Correspondence: katyccc@hotmail.com
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unless otherwise stated.population [5-8]; and comparable with rheumatoid arth-
ritis [9,10]. However, data were derived from cross sec-
tional studies that reflected the physical function at a
certain point of time which may be episodic, short last-
ing or long term disability. It is important to understand
variables that are associated with deterioration in phys-
ical function in psoriatic arthritis over time. There were
only a few studies on the longitudinal course of physical
function in PsA from Caucasian countries [11,12], while
physiotherapy was shown to improve physical function
in spondyloarthropathies (SpA) [13-15]. There are cul-
tural and ethnicity differences among Asian that affect
disease manifestation in PsA and SpA [16,17], which may
also affect disease progression and physical function. WeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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physical function over time in patients suffering from PsA.
In this study, we aim to describe the variables associated
with a change in physical function in Chinese patients with
psoriatic arthritis over a 6-year period, and to determine
the importance of joint damage and disease activity in the
deterioration of physical function.
Methods
Patient population
One hundred and twenty five consecutive out-patients
with PsA followed up in a single center were recruited
to assessment using a standardized protocol from January
2006 to May 2008. This rheumatology center overlooks a
population size of 628,634 and is the only secondary and
tertiary rheumatology referral center in the district. All
patients were adults, over 18 year-old and fulfilled the
Classification of Psoriatic Arthritis (CASPAR) criteria for
PsA [18]. The response rate was 91.2% (one patient
refused, 7 were not available during the study period and 4
were lost to follow up). The detailed baseline characteristic
and variables associated with physical function with the
first 80 patients were published elsewhere [6]. These PsA
patients were contacted for a follow up study from
June 2012 to May 2013 and filled in a set of patient
reported outcomes. A total of 97 patients responded to
invitation giving a response rate of 77.6%. Among non-
responders, 20 refused, 5 were lost to follow up and 3
patients died. Our study method was conducted with
adherence to the Strengthening the Reporting of Observa-
tional studies in Epidemiology guidelines.
Physical function assessment
Physical function was assessed by the Health Assessment
Questionnaire (HAQ) [19]. The Chinese HAQ was validated
in Singapore Chinese rheumatoid arthritis cohort [20].
The HAQ has been used in PsA populations and was
shown to be reliable and responsive to change [21-23].
Independent variables collected at baseline
Sociodemographic variables included age, gender, educa-
tion level, duration of psoraitc arthritis. Clinical features
included swollen, tender and damaged joint count in
66/68/68 diaarthrodial joints and the number of digits with
dactylitis (0–20). Damaged joints were defined as joints
ankylosed, subluxed, having > 20% decreased range of
movement and joints that have undergone joint replace-
ment, arthrodesis, arthroplasty or bone modification
alteration. Psoriasis was assessed by using the psoriasis
area-and-severity index (PASI) [24]. Entheseal disease was
assessed using the Maastricht Ankylosing Spondylitis
Entheses Score (MASES) [25]. The erythrocyte sedimenta-
tion rate (ESR) taken within the past 2 weeks were re-
corded. Physician’s global assessments of disease activity(PhGA), patient’s perception of pain and patients’ global
perception of joint and skin disease activity (PGA) were
captured on 11-point numeric rating scales. Quality of life
was assessed by the Chinese (Hong Kong) version of
Medical Outcomes Study Short Form health survey
(SF-36). The norm-based Physical component summary
scores (PCS) and Mental component summary scores
(MCS) were then formulated [26]. The presence or ab-
sences of erosions on hand radiograph (X-ray) and sacroi-
liitis on pelvis X-ray were read by a rheumatologist
blinded to patients’ clinical features. Sacroiliitis was de-
fined as grade 2 or above bilaterally or grade 3–4 unilat-
erally according to New York grading system [27].
Patient reported outcomes in follow up study
On follow up interview, patients were invited to self-fill
questionnaires including HAQ, SF36, pain score and pa-
tients’ perception of disease activity on 11-point numeric
rating scales. Patients were asked if they have ever used
disease modifying anti-rheumatic drugs (DMARDs),
including methotrexate, sulfasalazine, leflunomide, cyclo-
sporine A, hydroxychloroquine, chloroquine, azathioprine,
and others; or biological DMARD, including infliximab,
etanercept, adalimumab and golimumab.
The study protocols were reviewed and approved by the
Joint Chinese University of Hong Kong - New Territories
East cluster (CUHK-NTEC) clinical research ethics com-
mittees. Prior to the entry to the study, patients were
informed of the nature and purpose of the study and signed
informed consents.
Statistical analysis
Demographic and clinical characteristics were performed
using descriptive parametric or non-parametric statistics
as appropriate. The HAQ scores were divided into 3
categories: 0–0.49, 0.5–1.5, and 1.51–3, representing
minimal disability, moderate and severe disability. These
cut-offs were consistent with past studies on rheumato-
logy arthritis and inflammatory arthritis [28-30]. The
transition between status of disability from baseline to
follow up were classified as persistent no disability, per-
sistent moderate disability, HAQ deterioration and HAQ
improvement. The minimal clinical important difference
(MCID) for HAQ deterioration has been established with
an anchor method in 200 PsA patients (MCID = 0.13) [31]
and in a small sample of PsA patients in our center
undergoing anti-TNF therapy (MCID = 0.1) [32]. We took
a HAQ increment of > 0.2 for a secondary definition of
deterioration of physical function in this study.
Associations of functional outcomes with potential
clinical variables were tested with Mann–Whitney U test
for categorical variables or Spearman’s correlations for
continuous variables. Variables with p value < 0.05 were
taken as significant. As for multivariate analysis, the
Table 1 Characteristics of 97 patients participated in both
surveys
No. (%) of patients Mean ± SD
Baseline Follow up
Follow up time, years - 6.2 ± 0.7
Male (%) 53 (54.6) -
Age, years 48.2 ± 11.0 -
Ethnicity, Chinese 97 (100)
Duration of PsA years 8.1 ± 6.9 -
Education, years 8.7 ± 3.6 -
BMI, kg/m2 25.6 ± 4.4 -
ESR, mm/hour 33.0 ± 28.6 -
Tender joint count, 0-68 4.16 ± 5.10 -
Swollen joint count, 0-66 1.91 ± 2.69 -
Damage joint count, 0-68 2.97 ± 4.40 -
Dactylitis count, 0-20 0.58 ± 4.96 -
PASI, 0-72 5.62 ± 7.57 -
Pain, 0-10 4.96 ± 2.52 -
PGA, 0-10 4.52 ± 2.46 4.11 ± 2.64
PhGA, 0-10 2.12 ± 1.92 -
XR Sacroiliitis (%) 34 (35.1) -
XR hand erosion (%) 58 (59.8) -
HAQ 0.64 ± 0.59 0.43 ± 0.57
SF36
PCS (SD) 39.19 ± 8.65 36.05 ± 12.23
MCS (SD) 43.50 ± 11.47 45.42 ± 12.52
Ever use DMARD (%) 47 (48.5) 78 (80.4)
Ever use biologics (%) 0 22 (22.7)
BMI = body mass index. ESR = erythrocytes sedimentation rate. MASES =Mastraight
ankylosing spondylitis Enthese Score. PASI = Psoriasis area-and-severity
index. PGA = patients’ global perception of joint and skin disease activity.
PhGA = physician’s global assessments of disease activity. XR = plain radiography.
HAQ=Health Assessment Questionnaire. SF36 =Medical Outcome Short Form 36.
PCS =Hong Kong norm based Physical component Summary of SF36. MCS =Hong
Kong norm based Mental component Summary of SF36. DMARDs = Disease
modifying anti-rheumatic drugs.
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therefore transformed to Ln (1 + HAQ at follow up) for
analysis. In a multivariate analysis, independent variables
predicting Ln (1 + HAQ at follow up) were entered into
backwards linear regression analysis. All hypotheses were
2-tailed and p value < 0.05 were considered significant.
Independent variables entered into linear regression
model includes age, gender, duration of PsA (years),
Education (years), concurrent illness (yes/no), body mass
index, sacroiliitis (yes/no), tender joint count, swollen
joint count, damaged joint count, ESR, MASES, PASI,
PhGA, PGA, pain score, PCS, MCS, ever used DMARDs
and ever used biological DMARDs. Binary logistic
regression models were built for the same variables
predictive of 1). A deterioration of HAQ disability status;
and 2). Deterioration of HAQ scores of more than 0.2
over time. Analyses were performed using the IBM SPSS
Statistic Package, version 21.
Results
A total of 97 patients completed the follow up survey,
after a mean (±SD) follow up time of 6.2 (±0.7) years.
PsA affect adults in their middle age and affected indi-
vidual had poor physical function and consistently
poorer health related quality of life (HRQoL) compared
to normal population over time. There were 56.7%,
59.8% and 35.1% who had clinically damaged joints,
radiographic erosion of hand/ wrist joints and radio-
graphic sacroiliitis at baseline respectively. At baseline,
high percentages (41%) of patient have used DMARD
therapy; while utilization of biological agents was low
due to the non-reimbursement of medical expense.
Table 1 summarizes the characteristics of the patients
who completed both survey. There was no significant
difference in the baseline characteristics between the
28 patients who did not participated in the follow up
survey. (data not shown).
There were 41.7% of patients who had persistent
minimal disability by HAQ categories (HAQ 0–0.49)
over time, while 14.6% had persistent moderate disability
(HAQ 0.5-1.50) (Table 2). There were 33% who had
improvement in disability status and 10.3% had deterior-
ation in disability status. There were 17 patients who
had deterioration in physical function as defined by an
increment of HAQ score of more than 0.2 at the follow
up survey.
Independent variables associated with physical func-
tion at follow up as measured by HAQ included years of
education (p = 0.042), number of tender joint (p = 0.033),
number of damaged joint (p = 0.008), ESR (p = 0.031),
pain score (p < 0.0001), physicians’ global assessment
(p = 0.004), the PCS (p <0.0001) and MCS (p = 0.033)
of SF36. In multivariate analysis, age, baseline physical
function as measured by the PCS, and the number ofdamaged joint were related to HAQ at follow up
(Table 3). In the binary logistic regression models
using 1) deterioration of HAQ disability status; and
2) increment of HAQ > 0.2, no variable was found to
have significant association.
Discussion
This is the first longitudinal study on the course of PsA
in Chinese over time, showing deterioration of physical
function over time. One-fifth of patients had deterior-
ation of physical function more than the reported MCID.
Age, poorer physical function at baseline significantly
associated with poorer physical function, while the
number of damage joint was also related to physical
Table 2 The transition of HAQ disability status over
5 year period
HAQ at follow up Total
Minimal Moderate Severe
HAQ at baseline Minimal 40 5 0 45
Moderate 23 14 5 42
Severe 1 8 0 9
Total 64 27 5 96
HAQ = Health Assessment Questionnaire. HAQ categories: no (HAQ 0–0.49);
moderate (HAQ 0.5-1.50); severe (HAQ 1.51-3.0).
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of disease activities (pain level, number of tender joint
count, ESR and physician’s global assessment of disease
activity) were also associated with poorer physical func-
tion over time; but the association became insignificant
after adjustment of other factors. This is consistent of
our previous cross sectional study, demonstrating the sig-
nificant social and economic impact of PsA in Chinese,
and damaged joint were associated with poor functional
status [6].
There have been a few studies evaluating the longitu-
dinal course of physical function in PsA from Caucasian
countries [11,12]. However, differences in clinical mani-
festation among Asian patients with PsA have been de-
scribed [16], which limit direct extrapolation of results.
These include the exceptionally low prevalence of psor-
iasis and PsA among Japanese [33], high prevalence of
spinal involvement among Koreans [34], high percentage
of asymptomatic radiographic sacroiliitis among Chinese
[6,35], and high risk among Indians with psoriasis to
develop PsA as compared to Chinese [35,36]. To our
knowledge, this is the first longitudinal study in PsA co-
hort in Chinese. Psoriasis is less prevalent in China than
in Europe [37], and the prevalence of PsA in China seem
to be lower from a population-based study [38]. This
may explain the small sample size in our secondary/
tertiary center with a lengthy recruitment period. We
believe that this is a representative sample of PsA inTable 3 Multivariate regression analysis of variables associate
Clinical variables Standardized coefficients (Beta) 95%
(Constant)
Age 0.187 0.00
Damaged joint 0.174 −0.
PCS −0.403 −0.
CI = confident intervals. PCS = Hong Kong norm based Physical component Summa
Clinical variables entered into multivariate analysis.
Age, gender, duration of psoriatic arthritis (years), Education (years), concurrent illness (y
damaged joint count, ESR, Maastricht Ankylosing Spondylitis Entheses Score, Psoriasis ar
global perception of joint and skin disease activity, pain score, Hong Kong norm based
component Summary of SF36 (MCS), ever used disease modifying anti-rheumatic drugsthe region for two reasons. First, our primary health
care system was not established to provide long term care
for PsA patients; and second, with the financial reim-
bursement system and low utilization rate of anti-TNF, it
is also unlikely that patients with PsA were solely man-
aged in the dermatology setting without being referred to
rheumatology setting. Nevertheless, we demonstrated the
non-benign course of PsA. Two-third of patients had
clinically damaged joints and radiographic erosions, while
another third had sacroiliitis on X-rays at baseline. There
were poor physical function and HRQoL among PsA pa-
tients comparing to normal population at baseline and
over time. Over a 6-year period, one-fifth of PsA patients
experienced deterioration in physical function. Husted
et al. [11] evaluated the transition of three 3 physical
function status according to HAQ scores (0–0.49, 0.5–
1.5, and 1.51–3) in patients with PsA over a ten-year
period, 72% experienced either enduring disability or
moving between disability states. Comparing to Husted’s
cohort, a higher percentage of our patients seem to be re-
sistant to deterioration in physical function. There were
42% of our patients who had persistent minimal disease
activity (HAQ 0–0.49) and 15% had zero HAQ score at
both time points over the follow up period. However,
given a shorter follow up period and only having two
assessment time points, it would be difficult to draw a
definite conclusion.
We demonstrated age, educational level, disease activ-
ities (pain, tender joint count, ESR and physicians’ global
assessment), disease damage (damaged joint count) and
baseline physical function were associated with HAQ
over time. In general this is consistent with the Western
literature [11]. Advancing age and disability level at base-
line are associated with progression of disability among
elderly populations [39,40], elderly with arthritis [41], pa-
tients with rheumatoid arthritis (RA) [42] as well as in
patients with PsA [11]. Sheer at al [42] reported that age
was the single most powerful predictor of subsequent
disability in RA, but was also partially dependent on its
interrelationship with comorbidities and fragility. Femaled with HAQ at follow up
CI p Collinearity statistics
Tolerance VIF
0.005
0, 0.011 0.041 0.994 1.0006
001, 0.027 0.062 0.958 1.044
023, −0.009 <0.0001 0.963 1.038
ry of SF36.
es/no), body mass index, sacroiliitis (yes/no), tender joint count, swollen joint count,
ea-and-severity index, physician’s global assessments of disease activity, patients’
Physical component Summary of SF36 (PCS), Hong Kong norm based Mental
(DMARDs) and ever used biological DMARDs.
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disability in PsA [11], but not observed in our study. Joint
inflammation has been proposed as the main driver of
physical disability in the early stage of PsA; while joint
damage is considered the major determinant at later
stage. The detection of swollen joints was shown to pre-
cede the development of radiological joint damage in
PsA [43]. Husted at al [12] investigated the differential ef-
fects of disease activity and damage on physical function,
and the positive effects of actively inflamed joints on
HAQ score decreased over increasing duration of PsA;
and there was less evidence to suggest that the positive
effect of joint damage on the HAQ score increased over
time. Similar findings were revealed in our study. Da-
maged joint was significantly associated with HAQ in
our previous cross sectional study and the association
became marginal in the longitudinal dataset. This could
be the result of changes in disease activity, response to
drugs, coping strategies, and adaptation to the disease.
However, the baseline physical function remained a
significant factor associated with HAQ over time, re-
gardless of treatment. SpA patients on anti-TNF are
expected to have good functional outcomes [44], and
a short delay in diagnosis, male gender and preserved
physical function were predictors of minimal disease
activity (MDA) at the 5-year follow-up in a early PsA
cohort [45]. However, we were not able to demonstrate
the effect of anti-TNF in modulating the physical func-
tion at 6 year. This is probably related to the low
utilization rate of anti-TNF in our cohort and some pa-
tients had stop anti-TNF prematurely due to financial
constrain. Taking together with evidence of literature,
our findings support the treatment of joint inflamma-
tion in alleviating long term disability in patients suffer-
ing from PsA.
The strength of our study is the representative sample
of PsA in the region with reasonable sample size. Our
center is the only secondary and tertiary referral center
for PsA in the region, while there is essentially no pri-
mary health care other setting that provide long term
care for PsA. The response rate at baseline was high
and there was an acceptable response rate (77.6%)
at the 6-year follow up survey with high completion
of dataset. We used standardized and mostly validated
outcome measures according to standardized protocol
and clinical assessments at baseline were limited to
three clinicians experienced in PsA clinical trials. The
main limitation of our study is the small sample size. It
is the main reason why we were unable to demonstrate
predictive variables for deterioration of HAQ using two
definitions. Finally, we only have physical function data
at 2 time points and thus unable to tell whether func-
tional statuses were fluctuating or gradual declining
with time.Conclusion
We demonstrated Chinese patients with PsA had poor
physical function and quality of life. One fifth of patient
experienced deterioration of physical function over time.
Advancing age, baseline physical function and joint
damage were important factors associated with poor
physical function in PsA over time.
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